Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

Menter, 2008, Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics, J Am Acad Dermatol, 58, 826, 10.1016/j.jaad.2008.02.039 Schön, 2005, Engl J Med, 352, 1899, 10.1056/NEJMra041320 Hong, 2008, The psychosocial and occupational impact of chronic skin disease, Dermatol Ther, 21, 54, 10.1111/j.1529-8019.2008.00170.x Kimball, 2005, The psychosocial burden of psoriasis, Am J Clin Dermatol, 6, 383, 10.2165/00128071-200506060-00005 Koo, 1996, Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment, Dermatol Clin, 14, 485, 10.1016/S0733-8635(05)70376-4 Tsai, 2005, Current status and prospect for psoriasis treatment in Taiwan, Dermatol Sinica, 23, 69 Lew, 2004, Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and “Type 1” inflammatory gene expression, Trends Immunol, 25, 295, 10.1016/j.it.2004.03.006 Bissonnette, 2009, Safety of conventional systemic agents and biologic agents in the treatment of psoriasis, J Cutan Med Surg, 13, S67, 10.2310/7750.2009.00023 Thaçi, 2008, Long-term data in the treatment of psoriasis, Br J Dermatol, 159, 18, 10.1111/j.1365-2133.2008.08781.x Tsai, 2009, The use of biologics for psoriasis in Asia-Pacific region, Curr Rheumatol Rev, 5, 149, 10.2174/157339709789208615 Asahina, 2010, Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study, J Dermatol, 37, 299, 10.1111/j.1346-8138.2009.00748.x Na, 2008, Low-dose etanercept therapy in moderate to severe psoriasis in Korean, J Dermatol, 35, 484, 10.1111/j.1346-8138.2008.00508.x Torii, 2010, Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial, J Dermatol Sci, 59, 40, 10.1016/j.jdermsci.2010.04.014 Huang, 2008, Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study, J Eur Acad Dermatol Venereol, 22, 923, 10.1111/j.1468-3083.2007.02575.x Tsai, 2008, Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study, J Eur Acad Dermatol Venereol, 22, 345, 10.1111/j.1468-3083.2007.02430.x Oppmann, 2000, Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12, Immunity, 13, 715, 10.1016/S1074-7613(00)00070-4 Yawalkar, 1998, Expression of interleukin-12 is increased in psoriatic skin, J Invest Dermatol, 111, 1053, 10.1046/j.1523-1747.1998.00446.x Lee, 2004, Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris, J Exp Med, 199, 125, 10.1084/jem.20030451 Piskin, 2006, In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin, J Immunol, 176, 1908, 10.4049/jimmunol.176.3.1908 Hong, 1999, IL-12, independently of IFN-γ, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder, J Immunol, 162, 7480, 10.4049/jimmunol.162.12.7480 Aggarwall, 2003, Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17, J Biol Chem, 278, 1910, 10.1074/jbc.M207577200 Trinchieri, 2003, Interleukin-12 and the regulation of innate resistance and adaptive immunity, Nat Rev Immunol, 3, 133, 10.1038/nri1001 Tada, 2006, Interleukin-12 production by monocytes from patients with psoriasis and its inhibition by ciclosporin A, Br J Dermatol, 154, 1180, 10.1111/j.1365-2133.2006.07180.x Liu, 2008, A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci, PLoS Genet, 4, e1000041, 10.1371/journal.pgen.1000041 Nair, 2010, Genetic evidence for involvement of the IL23 pathway in Thai psoriatics, Arch Dermatol Res, 302, 139, 10.1007/s00403-009-0986-y Krueger, 2007, A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis, N Engl J Med, 356, 580, 10.1056/NEJMoa062382 Leonardi, 2008, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1), Lancet, 371, 1665, 10.1016/S0140-6736(08)60725-4 Papp, 2008, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2), Lancet, 371, 1675, 10.1016/S0140-6736(08)60726-6 Griffiths, 2010, Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis, N Engl J Med, 362, 118, 10.1056/NEJMoa0810652 Data on file. Centocor Research & Development. Fredriksson, 1978, Severe psoriasis: oral therapy with a new retinoid, Dermatologica, 157, 238, 10.1159/000250839 Finlay, 1994, Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use, Clin Exp Dermatol, 19, 210, 10.1111/j.1365-2230.1994.tb01167.x Lebwohl, 2010, Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial, Br J Dermatol, 162, 137, 10.1111/j.1365-2133.2009.09491.x Langley, 2010, Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial, J Am Acad Dermatol, 63, 457, 10.1016/j.jaad.2009.09.014 Chang, 2009, Epidemiological study of psoriasis in the national health insurance database in Taiwan, Acta Derm Venereol, 89, 262, 10.2340/00015555-0642 Tsai, 2011, Epidemiology and comorbidities of psoriasis patients in a National Database in Taiwan, J Dermatol Sci, 63, 40, 10.1016/j.jdermsci.2011.03.002 Nolan, 1999, Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic, JAMA, 281, 1014, 10.1001/jama.281.11.1014 Chiu HY, Hsueh PR, Tsai TF. Clinical experience of QuantiFERON®-TB Gold testing in psoriasis patients treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol; 2011;164:553-9. Kimball, 2008, National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening, J Am Acad Dermatol, 58, 1031, 10.1016/j.jaad.2008.01.006 Gelfand, 2006, Risk of myocardial infarction in patients with psoriasis, JAMA, 296, 1735, 10.1001/jama.296.14.1735 Neimann, 2006, Prevalence of cardiovascular risk factors in patients with psoriasis, J Am Acad Dermatol, 55, 829, 10.1016/j.jaad.2006.08.040 Lin, 2011, Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan, J Am Acad Dermatol, 64, 495, 10.1016/j.jaad.2010.01.050 Lebwohl M, Leonardi C, Griffiths CE, Prinz JC, Szapary PO, Yeilding N, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol; in press. Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol; in press. Reich, 2011, Cardiovascular safety of ustekinumab in patients with moderate-to-severe psoriasis: results of integrated analyses of data from phase II and III clinical studies, Br J Dermatol, 164, 862, 10.1111/j.1365-2133.2011.10257.x Lebwohl, 2010, Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations, J Am Acad Dermatol, 63, 571, 10.1016/j.jaad.2009.11.012 Lin, 2003, Prevalence of overweight and obesity and its associated factors: findings from National Nutrition and Health Survey in Taiwan, 1993–1996, Prev Med, 37, 233, 10.1016/S0091-7435(03)00119-1